Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CH.1.1.24NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.24NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.24NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.2.43NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.43NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.43NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.2.19NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.19NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BF.38.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.38.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.38.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BF.7.19.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.7.19.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.19.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BQ.1.1.43NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.43NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.43NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.2.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.12NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.12NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BF.7.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.7.23NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.23NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.214NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.214NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.214NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.284NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.284NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.284NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.351.3 (Beta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.351.3 (Beta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.351.3 (Beta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.318NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.318NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.318NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
R.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
R.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
R.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.29 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.29 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.29 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
ML.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
ML.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
ML.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.283NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.283NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used